Inventiva receives $10 million milestone payment from CTTQ

Core Viewpoint - Inventiva has received a $10 million milestone payment from Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (CTTQ) as part of their collaboration to develop lanifibranor for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) [1][3] Group 1: Financial Developments - The milestone payment follows the successful settlement of the second tranche of €115.6 million in gross proceeds from a structured financing deal of up to €348 million [2] - Under the CTTQ License Agreement, Inventiva is eligible to receive up to an additional $265 million in milestone payments and royalties on annual net sales of lanifibranor if approved [3] Group 2: Clinical Development - Lanifibranor has received Breakthrough Therapy Designation for MASH from both the U.S. FDA and the Chinese NMPA, which may expedite its development and regulatory review [4] - CTTQ is participating in the ongoing NATiV3 pivotal Phase 3 clinical trial for lanifibranor, which includes over 60 sites across mainland China [4] - A Phase I bridging study by CTTQ confirmed no significant ethnic differences, facilitating the regulatory approval process in China based on NATiV3 trial results [4] Group 3: Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for MASH, with lanifibranor being a novel pan-PPAR agonist currently evaluated in the NATiV3 Phase 3 clinical trial [5]